These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

244 related items for PubMed ID: 15929020

  • 1. [Tyrosine kinase inhibitors in tumor therapy--part 2. Current position and perspectives].
    Grimm CF, Blum HE, Geissler M.
    Dtsch Med Wochenschr; 2005 Jun 10; 130(23):1438-42. PubMed ID: 15929020
    [No Abstract] [Full Text] [Related]

  • 2. [Tyrosine kinase inhibitors in tumor therapy--part 1. Molecular and genetic fundamentals].
    Grimm CF, Blum HE, Geissler M.
    Dtsch Med Wochenschr; 2005 May 27; 130(21):1318-22. PubMed ID: 15902620
    [No Abstract] [Full Text] [Related]

  • 3. Current overview of angiogenesis inhibitors.
    Ellis LM.
    Clin Adv Hematol Oncol; 2004 Aug 27; 2(8):494-6, 520. PubMed ID: 16163228
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Beyond chemotherapy--demystifying the new 'targeted' cancer treatments.
    Dear R, Wilcken N, Shannon J.
    Aust Fam Physician; 2008 Aug 27; 37(1-2):45-9. PubMed ID: 18239753
    [Abstract] [Full Text] [Related]

  • 6. Pulmonary toxicities of tyrosine kinase inhibitors.
    Peerzada MM, Spiro TP, Daw HA.
    Clin Adv Hematol Oncol; 2011 Nov 27; 9(11):824-36. PubMed ID: 22252615
    [Abstract] [Full Text] [Related]

  • 7. [Antineoplastic agents targeting tyrosine kinases].
    Guren TK, Christoffersen T, Thoresen GH, Wisløff F, Dajani O, Tveit KM.
    Tidsskr Nor Laegeforen; 2005 Nov 17; 125(22):3115-9. PubMed ID: 16299568
    [Abstract] [Full Text] [Related]

  • 8. Clinical trials referral resource. Epidermal growth factor receptor inhibitors in clinical trials.
    Dancey JE, Schoenfeldt M.
    Oncology (Williston Park); 2001 Jun 17; 15(6):748-50, 756-8. PubMed ID: 11430207
    [No Abstract] [Full Text] [Related]

  • 9. [From ASCO and WCLC 2005 to the clinical practice: targeted therapies].
    Pérol M.
    Rev Pneumol Clin; 2006 Feb 17; 62 Spec no 1():1S30-4. PubMed ID: 16719154
    [No Abstract] [Full Text] [Related]

  • 10. Acquired resistance to tyrosine kinase inhibitors during cancer therapy.
    Engelman JA, Settleman J.
    Curr Opin Genet Dev; 2008 Feb 17; 18(1):73-9. PubMed ID: 18325754
    [Abstract] [Full Text] [Related]

  • 11. Targeted therapy in advanced non-small cell lung cancer (NSCLC): where do we stand?
    Azim HA, Ganti AK.
    Cancer Treat Rev; 2006 Dec 17; 32(8):630-6. PubMed ID: 17034953
    [Abstract] [Full Text] [Related]

  • 12. Salivary gland carcinomas: molecular abnormalities as potential therapeutic targets.
    Prenen H, Kimpe M, Nuyts S.
    Curr Opin Oncol; 2008 May 17; 20(3):270-4. PubMed ID: 18391625
    [Abstract] [Full Text] [Related]

  • 13. [Molecular target therapy for malignant tumors].
    Nihon Naika Gakkai Zasshi; 2005 Feb 20; 94 Suppl():76-80. PubMed ID: 15796061
    [No Abstract] [Full Text] [Related]

  • 14. [Lung cancer: molecular targeting therapy].
    Kobayashi K.
    Nihon Kokyuki Gakkai Zasshi; 2004 May 20; 42(5):371-7. PubMed ID: 15168452
    [No Abstract] [Full Text] [Related]

  • 15. Recent success with the tyrosine kinase inhibitor STI-571--lessons for targeted therapy of cancer.
    Shah NP, Sawyers CL.
    Curr Opin Investig Drugs; 2001 Mar 20; 2(3):422-3. PubMed ID: 11575716
    [No Abstract] [Full Text] [Related]

  • 16. Targeted therapies in the treatment of advanced non-small-cell lung cancer: update.
    Mendoza L.
    Klin Onkol; 2009 Mar 20; 22(4):131-8. PubMed ID: 19731875
    [Abstract] [Full Text] [Related]

  • 17. Anti-angiogenic and anti-HER therapy.
    Gasparini G, Sarmiento R, Longo R.
    Biomed Pharmacother; 2006 Jul 20; 60(6):263-5. PubMed ID: 16815667
    [Abstract] [Full Text] [Related]

  • 18. Epidermal growth factor receptor inhibitors: a moving target?
    Bates SE, Fojo T.
    Clin Cancer Res; 2005 Oct 15; 11(20):7203-5. PubMed ID: 16243788
    [No Abstract] [Full Text] [Related]

  • 19. YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors.
    Amino N, Ideyama Y, Yamano M, Kuromitsu S, Tajinda K, Samizu K, Hisamichi H, Matsuhisa A, Shirasuna K, Kudoh M, Shibasaki M.
    Clin Cancer Res; 2006 Mar 01; 12(5):1630-8. PubMed ID: 16533791
    [Abstract] [Full Text] [Related]

  • 20. Tyrosine kinases as targets for cancer therapy.
    Krause DS, Van Etten RA.
    N Engl J Med; 2005 Jul 14; 353(2):172-87. PubMed ID: 16014887
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.